Iron deficiency in gastrointestinal oncology

Annals of Gastroenterology

Volumn 28, Issue 1, 2015, Pages 19-24

  Verraes, Kristof ^a   Prenen, Hans ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Anemia; Digestive oncology; Iron deficiency

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; FERROUS GLUCONATE; FERROUS SULFATE; IRON; IRON DEXTRAN; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ANAPHYLAXIS; ANEMIA; ARTICLE; CANCER PATIENT; DIAGNOSTIC PROCEDURE; DIGESTIVE SYSTEM CANCER; DRUG FORMULATION; FERRITIN BLOOD LEVEL; HOMEOSTASIS; HUMAN; IRON DEFICIENCY; IRON METABOLISM; MONOTHERAPY; PATHOGENESIS; PREVALENCE;

EID: 84920480997     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
2. Clarke H, Pallister CJ. The impact of anaemia on outcome in cancer. Clin Lab Haematol 2005;27:1-13.
3. Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol 2001;28:7-14.
4. Holzner B, Kemmler G, Greil R, et al. The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 2002;13:965-973.
5. Lind M, Vernon C, Cruickshank D, et al. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 2002;86:1243-1249.
6. Ludwig H, Aapro M, Bokemeyer C, et al. A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Support Care Cancer 2014;22:2197-2206.
7. Schrijvers D. Management of Anemia in cancer patients: transfusions. Oncologist 2011;16:12-18.
8. Bohlius J, Weingart O, Treele S, Engert A. Cancer-related anemia and recombinant human erythropoietin – an updated overview. Nat Clin Pract Oncol 2006;3:152-164.
9. Rodgers GM 3rd, Becker PS, Blinder M, et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2012;10:628-653.
10. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology and the American Society of Clinical Oncology Practice Guideline Update Committee. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010;116:4045-4059.
11. Schrijvers D, De Samblanx H, Roila F; ESMO Guidelines Working Group. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 2010;21(Suppl 5):v244-v247.
12. Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database of Syst Rev 2012;12: CD003407.
13. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007;11:1-202.
14. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients witch chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-1307.
15. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patiensts with cancer receiving chemotherapy. Oncologist 2007;12:231-242.
16. Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients witch lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21:627-632.
17. Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and sefety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611-1618.
18. Pedrazzolli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008;26:16919-1625.
19. Goodnough LT. Erythropoietin and iron-restricted erythropoiesis. Exp Hematol 2007;35:167-172.
20. Ludwig H, Müldür E, Endler G, Hübl W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 2013;24:1886-1892.
21. Muñoz M, Villar I, García-Erce JA. An update on iron physiology. World J Gastroenterol 2009;15:4617-4626.
22. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;341:1986-1995.
23. Fleming RE, Bacon BR. Orchestration of iron homeostasis. N Eng J Med 2005;352:1741-1744.
24. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Act 2012;1823:1434-1443.
25. Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009;113:5277-5286.
26. Goodnough LT. Iron deficiency syndromes and iron-restricted erythropoiesis. Transfusion 2012;52:1584-1592.
27. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006;1:S4-S8.
28. Steinmetz HT, Tsamaloukas A, Schmitz S, et al. A new concept for the differential diagnosis and therapy of anaemia in cancer patients. Support Care Cancer 2010;19:261-269.
29. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004;15:S93-S98.
30. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006:21:378-382.
31. Fletes R, Lazarus JM, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 2001;37:743-749.
32. Beguin Y, Aapro M, Ludwig H, Mizzen L, Osterborg A. Epidemiological and nonclinical studies investigating effects of iron carcinogenesis – a critical review. Crit Rev Oncol Hematol 2014;89:1-15.
33. Steensma DP, Sloan JA, Dakhill SR, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoetic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2010;29:97-105.
34. Kim YT, Kim SW, Yoon BS, et al. Effect of intravenously iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007;105:199-204.
35. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patient receiving chemotherapy. Gynecol Oncol 2010;116:522-525.
36. Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 2013;24:475-482.